方盛製藥(603998.SH):諾麗通顆粒已取得了Ⅲ期臨牀研究總結報吿,目前正在申報註冊中
格隆匯3月9日丨方盛製藥(603998.SH)於2023年3月7日接受老虎太平洋基金的調研並表示,公司的諾麗通顆粒已取得了Ⅲ期臨牀研究總結報吿,目前正在申報註冊中。諾麗通顆粒是天津中醫學院第一附屬醫院閆莉主任醫師在中國近代著名中醫大家張錫純先生的代表性方劑“升陷湯”的基礎上加減而成,能夠直接升提氣血至頭部,改善腦供血不足情況,迅速緩解頭痛、頭暈症狀,多年應用於臨牀治療反覆發作性緊張型頭痛,療效顯著。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.